Cadila Healthcare, a global pharmaceuticals company, and Zydus
Pharmaceuticals (USA), Inc., a leading generic pharmaceutical company in
the United States, have entered into a settlement agreement with
Depomed, Inc. to settle their ongoing patent infringement litigation
related to Gralise (gabapentin) 300 mg and 600 mg tablets. The
settlement permits Cadila and Zydus to begin selling generic versions of
Gralise on January 1, 2024, or earlier under certain circumstances.For more information ✆ - 0731-6642300 or Visit https://www.epicresearch.co/
No comments:
Post a Comment